Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +37.72%
#2 Versatize Coin Versatize Coin +32.51%
#3 Siren Siren +30.99%
#4 Purr Purr +28.11%
#5 Official Trump Official Trump +20.50%
#6 OriginTrail OriginTrail +17.22%
#7 Prom Prom +17.05%
#8 ApeX ApeX +16.64%
#9 UnifAI Network UnifAI Network +15.84%
#10 Pendle Pendle +14.37%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Rang in aandelen #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Aandeelprijs
$50.82
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$102.09M
Verandering (1 dag)
1.90%
Verandering (1 jaar)
-
Land
US
Handel Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Categorie

Healthcare
Winst voor Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Hemab Therapeutics Holdings, Inc. Common Stock bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Hemab Therapeutics Holdings, Inc. Common Stock van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH